Protalix BioTherapeutics (PLX) Cash from Financing Activities (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Cash from Financing Activities of $150000.0 for Q1 2026, down 97.04% year-over-year from $5.1 million in Q1 2025, and up 2.74% quarter-over-quarter from $146000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $150000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 97.04% year-over-year to $150000.0; the TTM figure through Mar 2026 stood at $4.4 million (down 49.44% YoY), while the FY2025 annual figure was $9.3 million, up 155.53% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $150000.0, up from $146000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $14.2 million in Q1 2023, with the low at $146000.0 in Q4 2025.
- The 5-year median for Cash from Financing Activities is $4.1 million (2022), against an average of $4.8 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities surged 200.72% in 2022, then slumped 97.04% in 2026.
- Protalix BioTherapeutics' Cash from Financing Activities stood at $4.1 million in 2022, then surged by 156.02% to $10.4 million in 2023, then slumped by 65.24% to $3.6 million in 2024, then tumbled by 95.97% to $146000.0 in 2025, then advanced by 2.74% to $150000.0 in 2026.
- Business Quant data shows PLX's Cash from Financing Activities at $150000.0 in Q1 2026, $146000.0 in Q4 2025, and $4.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 150,000.00 |
| Mar 31, 2026 | 150,000.00 |
| Dec 31, 2025 | 146,000.00 |
| Dec 31, 2025 | 146,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Dec 31, 2024 | 3.63 Mn |
| Dec 31, 2024 | 3.63 Mn |
| Jun 30, 2023 | 10.43 Mn |
| Jun 30, 2023 | 10.43 Mn |
| Mar 31, 2023 | 14.23 Mn |
| Mar 31, 2023 | 14.23 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Dec 31, 2021 | -4.05 Mn |
| Dec 31, 2021 | -4.05 Mn |